必发彩票,必发彩票开户,必发彩票注册,必发彩票代理,必发彩票官网,必发彩票网址,必发彩票交流群

Baidu

必发彩票中国医学科学院北京协和医学院血液病医院(血液学研究所)(以下简称“院所”)由中国血液学创始人邓家栋教授创建于1957年。七十年代迁往四川,1982年重新迁回天津。   90年代以来,随着我国血液学事业的发展和医疗市场的变化,院所不断开拓创新,必发彩票谋求血液学事业的新发展。从容不从众,追求创新,精髓不变是我们的办院方针。为把医院做“特”,科研做“精”,我们改“大所小院”为“大院小所”,由过去200张床位的“小综合”,发展为600余张床位的血液病“大专科”,由过去一个大血液内科发展为按病种和功能设置的12个临床中心的专科医院;以实验血液学国家重点实验室为龙头,围绕实验血液学和干细胞研究凝炼研究方向,建立了精干的基础研究队伍。

 
邱录贵课题组与常洪课题组合作在Clinical Cancer Research期刊发表文章

  我所邱录贵课题组与常洪课题组合作在Clinical Cancer Research期刊发表文章“ miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma ”。

Abstract

  

PURPOSE:

  Deregulation of miRNA has been implicated in the pathogenesis of multiple myeloma. We identified miR-137 and miR-197, mapped to the chromosome 1p (12)-(21) deletion region, and examined their antimyeloma activity as tumor suppressors.

EXPERIMENTAL DESIGN:

  The expression of miR-137/197 was examined in multiple myeloma and normal plasma cells by qRT-PCR. Functional effect of miR-137/197 was analyzed by cell viability, apoptosis, clonogenic, and migration assays. Antimyeloma activity of miR-137/197 was further evaluated in vivo by lentiviral-based or lipid-based delivery in a mouse xenograft model of multiple myeloma.

RESULTS:

  miR-137/197 expression was significantly lower in multiple myeloma cell lines and multiple myeloma patient samples compared with normal plasma cells. Transfection of miR-137/197 resulted in reduction of MCL-1 protein expression, as well as alteration of apoptosis-related genes, and induction of apoptosis, inhibition of viability, colony formation, and migration in multiple myeloma cells. MCL-1 was further validated as a direct target of miR-137/197. Conversely, overexpression of MCL-1 partially reverted the effect of miR-137/197. Importantly, in vivo lentiviral-mediated or intratumor delivery of miR-137/197 induced regression of tumors in murine xenograft models of multiple myeloma.

CONCLUSIONS:

  Our study reveals a novel role of miR-137/197 as tumor suppressors in mediating apoptosis in multiple myeloma cells by targeting MCL-1. Our findings provide a proof-of-principle that lentivirus-based or formulated synthetic miR-137/197 exerts therapeutic activity in preclinical models, and support a framework for development of miR-137/197-based treatment strategies in patients with multiple myeloma.

  ©2015 American Association for Cancer Research.

查阅原文链接

   
网站导航 | 联系我们 | 使用帮助 | 网站声明


必发彩票www.munasprok.com版权所有  技术支持:北方网
  备案序号:津ICP备05001070号
建议使用IE6.0以上浏览器,分辨率1024*768